DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+24.11%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.85B
AUM Growth
+$276M
(+11%)
Cap. Flow
-$74.2M
Cap. Flow
% of AUM
-2.6%
Top 10 Holdings %
Top 10 Hldgs %
41.33%
Holding
76
New
13
Increased
15
Reduced
16
Closed
18
Top Buys
| 1 |
argenx
ARGX
|
$114M |
| 2 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$52.8M |
| 3 |
Sarepta Therapeutics
SRPT
|
$48.2M |
| 4 |
Tourmaline Bio
TRML
|
$47.5M |
| 5 |
ABVX
Abivax
ABVX
|
$46M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$134M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$80.2M |
| 3 |
Immunovant
IMVT
|
$75.7M |
| 4 |
Structure Therapeutics
GPCR
|
$65.8M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
26
Abivax
ABVX
$6.32B
| $46M | 1.54% |
+4,297,438
| New | +$46M |
|
27
RAPT Therapeutics
RAPT
$187M
| $44.6M | 1.49% |
224,246
+36,746
| +20% | +$7.31M |
|
28
AnaptysBio
ANAB
$630M
| $43.6M | 1.46% |
2,036,990
+691,177
| +51% | +$14.8M |
|
|
29
Immunovant
IMVT
$2.91B
| $42.1M | 1.41% |
1,000,000
-1,797,955
| -64% | -$75.7M |
|
30
Spyre Therapeutics
SYRE
$1.02B
| $42M | 1.4% |
+1,952,760
| New | +$42M |
|
31
Ocular Therapeutix
OCUL
$2.25B
| $41.2M | 1.37% |
+9,230,769
| New | +$41.2M |
|
32
Arcellx
ACLX
$3.95B
| $40.2M | 1.34% |
+725,145
| New | +$40.2M |
|
33
Terns Pharmaceuticals
TERN
$651M
| $39.6M | 1.32% |
6,100,000
+100,000
| +2% | +$649K |
|
|
SLN
34
Silence Therapeutics
SLN
$246M
| $33.9M | 1.13% |
1,951,580
| – | – |
|
|
ORTX
35
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $33.6M | 1.12% |
2,041,670
| – | – |
|
36
Nuvalent
NUVL
$5.74B
| $33.1M | 1.11% |
+450,000
| New | +$33.1M |
|
37
ANI Pharmaceuticals
ANIP
$2.06B
| $33.1M | 1.1% |
600,000
+200,000
| +50% | +$11M |
|
38
Nurix Therapeutics
NRIX
$723M
| $30.9M | 1.03% |
2,997,830
| – | – |
|
39
Edgewise Therapeutics
EWTX
$1.54B
| $27.8M | 0.93% |
2,537,176
-212,824
| -8% | -$2.33M |
|
40
Olema Pharmaceuticals
OLMA
$432M
| $27.1M | 0.9% |
1,930,894
| – | – |
|
41
Dyne Therapeutics
DYN
$1.92B
| $26.6M | 0.89% |
2,000,000
-403,672
| -17% | -$5.37M |
|
|
AGEN
42
Agenus
AGEN
$136M
| $26.2M | 0.88% |
1,584,877
| – | – |
|
43
Cytokinetics
CYTK
$5.98B
| $24.1M | 0.81% |
+288,949
| New | +$24.1M |
|
44
Agios Pharmaceuticals
AGIO
$2.36B
| $23.7M | 0.79% |
1,062,881
+640,634
| +152% | +$14.3M |
|
45
Repare Therapeutics
RPTX
$73M
| $21.8M | 0.73% |
2,992,731
-75,000
| -2% | -$548K |
|
46
Scholar Rock
SRRK
$3.3B
| $19M | 0.64% |
1,011,829
+657,974
| +186% | +$12.4M |
|
|
47
Structure Therapeutics
GPCR
$1.15B
| $12.2M | 0.41% |
300,000
-1,615,000
| -84% | -$65.8M |
|
48
Zura Bio
ZURA
$132M
| $11.8M | 0.39% |
2,523,000
| – | – |
|
49
Nektar Therapeutics
NKTR
$543M
| $10.4M | 0.35% |
1,226,667
| – | – |
|
50
Relmada Therapeutics
RLMD
$48.8M
| $8.46M | 0.28% |
2,044,507
-793,311
| -28% | -$3.28M |
|